Cancer‐stroma interactions affect tumorigenesis, angiogenesis, therapy resistance and, possibly, the metastatic spread of tumor cells.69 In fact, no objective response was observed in 14 pancreatic cancer (PC) patients treated with BMS‐936559, an anti‐PD‐L1 antibody (Table 2).60 Therefore, targeting the tumor stroma offers a promising new option for the treatment of PDAC. The gene discussed is CD274; the disease is neoplasm.